Novo Nordisk A/S – Reduction of the share capital
April 27 2021 - 9:14AM
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 27 April
2021 – At Novo Nordisk’s Annual General Meeting on 25
March 2021, it was decided to reduce the company’s B share capital
from DKK 362,512,800 to DKK 354,512,800 by cancellation of part of
the company’s portfolio of own B shares equal to a nominal value of
DKK 8,000,000 divided into 40,000,000 B shares of DKK 0.20
each.
Today, Novo Nordisk has registered the implementation of the
reduction of the share capital with the Danish Business Authority
and cancelled B shares at a nominal value of DKK 8,000,000. After
the reduction of the share capital, the company’s share capital is
nominally DKK 462,000,000, which is divided into an A share capital
of nominally DKK 107,487,200 and a B share capital of nominally DKK
354,512,800.
The reduction of the share capital will not affect Novo
Nordisk’s share repurchase programme which will continue as
previously announced.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No. 27 / 2021
- CA_210427_CapitalReduction
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024